Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Current Assets (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed Current Assets for 13 consecutive years, with $96.8 million as the latest value for Q4 2025.

  • Quarterly Current Assets rose 51.02% to $96.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $96.8 million through Dec 2025, up 51.02% year-over-year, with the annual reading at $96.8 million for FY2025, 51.02% up from the prior year.
  • Current Assets for Q4 2025 was $96.8 million at Niagen Bioscience, up from $93.6 million in the prior quarter.
  • The five-year high for Current Assets was $96.8 million in Q4 2025, with the low at $37.9 million in Q3 2022.
  • Average Current Assets over 5 years is $57.1 million, with a median of $49.3 million recorded in 2024.
  • The sharpest move saw Current Assets crashed 33.53% in 2022, then soared 79.57% in 2025.
  • Over 5 years, Current Assets stood at $48.9 million in 2021, then dropped by 4.78% to $46.6 million in 2022, then rose by 6.37% to $49.5 million in 2023, then increased by 29.41% to $64.1 million in 2024, then surged by 51.02% to $96.8 million in 2025.
  • According to Business Quant data, Current Assets over the past three periods came in at $96.8 million, $93.6 million, and $86.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.